At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 18 enrolled
Drug / intervention
Tezepelumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Open-label Study to Evaluate the Pharmacokinetics of Tezepelumab in Children ≥ 5 to 11 Years of Age With Mild, Moderate, or Severe Asthma (TRAILHEAD)
In Brief
A Phase 1 clinical trial evaluating Tezepelumab for Asthma. Completed, enrolled 18 participants across 6 sites in 3 countries.
Detailed Summary
This study will evaluate the pharmacokinetic (PK) profile of a single subcutaneous (SC) dose of tezepelumab in children aged ≥ 5 to 11 years with asthma.
Study Details
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedDec 2020
Enrollment StartFeb 2021
Primary CompletionSep 2022
TodayJul 2026
First PostedDec 17, 2020
Enrollment StartFeb 23, 2021
Primary CompletionSep 27, 2022
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 5.5 years ago
Interventions
Tezepelumabbiological
Single dose subcutaneous injection